ABBV Jan 2024 85.000 call
| Previous close | 69.30 |
| Open | 69.27 |
| Bid | 61.50 |
| Ask | 62.35 |
| Strike | 85.00 |
| Expiry date | 2024-01-19 |
| Day's range | 69.27 - 69.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
- Zacks
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
- Motley Fool
2 of the Best Dividend Stocks to Own in 2023
In either case, it's a good idea to add some dividend stocks to your portfolio. If you want to benefit from passive income and potential growth, I've got two stocks in mind. The stocks I'm talking about also have reached a turning point that could lead to earnings growth down the road.
- PR Newswire
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.
